ELI-005
/ Elicio Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 30, 2022
Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates.
(PubMed, NPJ Vaccines)
- "Here we evaluated an Amphiphile (AMP) adjuvant, AMP-CpG, admixed with SARS-CoV-2 Spike receptor binding domain (RBD) immunogen, as a lymph node-targeted protein subunit vaccine (ELI-005) in mice and non-human primates (NHPs). Expansion of RBD-specific germinal center (GC) B cells in lymph nodes correlated to rapid seroconversion with variant-specific neutralizing antibody responses exceeding those measured in convalescent human plasma. These results demonstrate the promise of lymph-node adjuvant-targeting to coordinate innate immunity and generate robust adaptive responses critical for vaccine efficacy."
Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
February 07, 2021
A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
(PubMed, Sci Adv)
- "Here, we evaluated an Amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) in mice...Both cellular and humoral immune responses were preserved in aged mice. These advantages merit clinical translation to SARS-CoV-2 and other protein subunit vaccines."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 2
Of
2
Go to page
1